We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Aratana Therapeutics (PETX) Worth a Look: Stock Gains 6.2%
Aratana Therapeutics, Inc. was a big mover last session, as the company saw its shares rise over 6% on the day. The upside was driven by the company’s announcement of better-than-expected top- and bottom-line results for second-quarter 2016. This led to solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $6.45 to $8.00 in the past one-month time frame.
The company has seen no estimate revisions over the past 30 days, while the Zacks Consensus Estimate remained unchanged over the same time frame. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Aratana Therapeutics currently has a Zacks Rank #3 (Hold).
ARATANA THERAP Price
ARATANA THERAP Price | ARATANA THERAP Quote
A better-ranked stock in the Med-Drugs industry is Achaogen, Inc. , which sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>